| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/28/2005 | EP1578816A1 Polymeric boronic acid derivatives as lipase inhibitors |
| 09/28/2005 | EP1578798A1 Ghrelin receptor inverse agonist for regulation of feeding behaviours |
| 09/28/2005 | EP1578773A2 Methods and products based on oligomerization of stress proteins |
| 09/28/2005 | EP1578760A2 Compositions and methods for the diagnosis and treatment of tumor |
| 09/28/2005 | EP1578758A2 Purine nucleosides |
| 09/28/2005 | EP1578755A1 Phosphonooxy quinazoline derivatives and their pharmaceutical use |
| 09/28/2005 | EP1578751A1 Pyrrolopyrimidine derivatives |
| 09/28/2005 | EP1578748A1 Tetrahydro-4h-pyrido [1, 2-a] pyrimidines and related compounds useful as hiv integrase inhibitors |
| 09/28/2005 | EP1578746A1 Oxazoles as mglur1 enhancer |
| 09/28/2005 | EP1578743A2 Antibacterial agents |
| 09/28/2005 | EP1578738A1 Escitalopram hydrobromide and a method for the preparation thereof |
| 09/28/2005 | EP1578735A1 Cyclopentyl glutaramides and their use as neutral endopeptidase inhibitors |
| 09/28/2005 | EP1578734A1 Novel antibacterial agents |
| 09/28/2005 | EP1578727A2 Tetrahydroquinoline derivatives and their use as fsh receptor modulators |
| 09/28/2005 | EP1578726A2 Tetrahydroquinoline derivatives |
| 09/28/2005 | EP1578724A2 Mitotic kinesin inhibitors |
| 09/28/2005 | EP1578723A2 Process for the preparation of oxazolidinones and method of use thereof |
| 09/28/2005 | EP1578722A2 Kinase inhibitor scaffolds and methods for their preparation |
| 09/28/2005 | EP1578721A2 Processes for the preparation of substituted isoxazoles and 2-isoxazolines |
| 09/28/2005 | EP1578719A2 Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| 09/28/2005 | EP1578717A2 Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain |
| 09/28/2005 | EP1578716A1 Dicarboxylic acid derivatives as ppar-agonists |
| 09/28/2005 | EP1578513A2 INTEGRATION OF AT LEAST TWO PROCESSES TO RE−USE ACID |
| 09/28/2005 | EP1578454A1 Ultrasound contrast using halogenated xanthenes |
| 09/28/2005 | EP1578450A1 Amplification of biotin-mediated targeting |
| 09/28/2005 | EP1578449A2 Compositions of benzoquinolizine carboxylic acid antibiotic drugs |
| 09/28/2005 | EP1578448A1 Compositions of cholesteryl ester transfer protein inhibitors and hmg-coa reductase inhibitors |
| 09/28/2005 | EP1578441A2 Polyphosphazene immunocstimulants |
| 09/28/2005 | EP1578434A2 Methods and compositions relating to isoleucine boroproline compounds |
| 09/28/2005 | EP1578431A2 Fat regulation |
| 09/28/2005 | EP1578430A2 Treatment of diabetes |
| 09/28/2005 | EP1578429A2 Protease inhibitors |
| 09/28/2005 | EP1578428A2 Treating alcohol and or substance abuse by antagonizing alpha a2 drenergic receptors with weak dopamine blocking |
| 09/28/2005 | EP1578427A1 Use of gnrh agonists to support the luteal phase during infertility treatment |
| 09/28/2005 | EP1578426A1 Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia |
| 09/28/2005 | EP1578425A1 Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists |
| 09/28/2005 | EP1578424A2 Substituted 1-benzoyl-3-cyano-pyrrolo 1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis |
| 09/28/2005 | EP1578422A2 A physically and chemically stable nicotine-containing particulate material |
| 09/28/2005 | EP1578421A2 Pharmaceutical preparations for treatments of diseases and disorders of the breast |
| 09/28/2005 | EP1578420A2 Treatment of cognitive impairment using a selective dopamine d1 receptor agonist |
| 09/28/2005 | EP1578419A2 Immunostimulatory combinations |
| 09/28/2005 | EP1578418A2 Use of substituted 2,5-diamidoindoles for the treatment of urological diseases |
| 09/28/2005 | EP1578417A1 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators |
| 09/28/2005 | EP1578416A1 Medicaments containing substituted 2,5-diaminomethyl-1h-pyrroles |
| 09/28/2005 | EP1578415A1 Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| 09/28/2005 | EP1578414A2 Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 09/28/2005 | EP1578413A2 Ace-inhibitors having antioxidant and no-donor activity |
| 09/28/2005 | EP1578412A2 Pharmaceutical compositions and method of treating parkinson's disease |
| 09/28/2005 | EP1578411A1 Methods for selectively inhibiting janus tyrosine kinase 3 (jak3) |
| 09/28/2005 | EP1578410A1 Method for preventing abuse of methylphenidate |
| 09/28/2005 | EP1578409A1 Uses of adenosine a2a receptor antagonists |
| 09/28/2005 | EP1578408A2 Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect |
| 09/28/2005 | EP1578403A2 Modified release compositions of milnacipran |
| 09/28/2005 | EP1578401A2 Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
| 09/28/2005 | EP1578363A2 Novel druggable regions in set domain proteins and methods of using the same |
| 09/28/2005 | EP1578362A2 Boroproline compound combination therapy |
| 09/28/2005 | EP1578360A2 Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure |
| 09/28/2005 | EP1578359A2 Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof |
| 09/28/2005 | EP1578355A2 Improved compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
| 09/28/2005 | EP1578353A2 Methods of use and compositions for the diagnosis and treatment of infectious disease |
| 09/28/2005 | EP1578352A2 Elastin prevents occlusion of body vessels by vascular smooth muscle cells |
| 09/28/2005 | EP1578351A2 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| 09/28/2005 | EP1578350A2 Sustained-release gel coated compositions |
| 09/28/2005 | EP1578349A2 Novel anti-bacterial compositions |
| 09/28/2005 | EP1578346A2 Raf-mek-erk pathway inhibitors to treat cancer |
| 09/28/2005 | EP1578342A2 Process for preparation of programmed liberation composition with venlafaxine and the resulting product |
| 09/28/2005 | EP1578341A2 Modulation of ccr4 function |
| 09/28/2005 | EP1578294A1 Methods and systems for enabling and stabilizing tooth movement |
| 09/28/2005 | EP1578252A2 Methods for evaluating genetic susceptibility and therapy for chronic inflammatory diseases |
| 09/28/2005 | EP1578214A1 Food composition comprising a satiety enhancing amount of triacylglycerol and use in the manufacture of a medicament for the treatment or prevention of obesity |
| 09/28/2005 | EP1578193A2 Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
| 09/28/2005 | EP1463731B1 Dibenzodiazepine derivates, their preparation and use |
| 09/28/2005 | EP1448521B1 Derivatives of andrimide and moiramide b having antibacterial properties |
| 09/28/2005 | EP1442033B1 Omega-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists |
| 09/28/2005 | EP1439849A4 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
| 09/28/2005 | EP1420804A4 Methods and compositions for control of coccidiosis |
| 09/28/2005 | EP1411936B1 Use of thiazole derivatives for the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease |
| 09/28/2005 | EP1401438B1 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
| 09/28/2005 | EP1397348B1 Factor xa inhibitor |
| 09/28/2005 | EP1373258B1 Ether derivatives useful as inhibitors of pde4 isozymes |
| 09/28/2005 | EP1366029B1 Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolins and the utilization thereof as anticoagulant and antithrombotic agents |
| 09/28/2005 | EP1361880B1 6-substituted pyrido-pyrimidines |
| 09/28/2005 | EP1345937B1 Quinuclidine carbamate derivatives and their use as m3 antagonists |
| 09/28/2005 | EP1320357A4 Topical polymeric antimicrobial emulsion |
| 09/28/2005 | EP1318815B1 Use of the combination of nicotinic acid or derivatives with riboflavin in the manufacture of a medicament for the treatment of primary headaches |
| 09/28/2005 | EP1307430B1 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists |
| 09/28/2005 | EP1299365B1 2-aminothiazoline derivatives and their use as no-synthase inhibitors |
| 09/28/2005 | EP1299103B1 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors |
| 09/28/2005 | EP1292598B1 Process for drying amoxicillin |
| 09/28/2005 | EP1289559B8 Combinations of enzyme inhibitor-containing preparations and the use thereof |
| 09/28/2005 | EP1274458B1 Compositions containing a naphthalmide and an antiproliferative agent |
| 09/28/2005 | EP1265838B1 Novel fatty acid analogous |
| 09/28/2005 | EP1263401B1 Oral composition comprising 2'-hydroxypropiophenone |
| 09/28/2005 | EP1259622B1 Nucleotide sequences encoding proteins that take part in the biosynthesis of l-serine, improved method for microbially producing l-serine, and genetically modified microorganism suitable for use in said method |
| 09/28/2005 | EP1255546B9 Method for improving bone modeling and chondrocyte functioning in growing canines |
| 09/28/2005 | EP1243583B1 Heterocyclic compounds having sulfonamide groups |
| 09/28/2005 | EP1242397B1 Trans olefinic glucokinase activators |
| 09/28/2005 | EP1228072B1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 09/28/2005 | EP1225173B1 Naphthyridine derivatives |
| 09/28/2005 | EP1210348B1 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them |